HighTower Advisors
ICPT

HighTower Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

HighTower Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-38,618
Closed -$3.89M – 2452
2018
Q4 		$3.89M Sell
38,618
-16,215
-30% -$1.68M 0.03% 532
2018
Q3 		$6.93M Buy
+54,833
New +$5.8M 0.05% 400

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HighTower Advisors's ICPT Position: Q1 2019 in Review

HighTower Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 38,618 shares — an estimated $3.89M sold.

HighTower Advisors first reported a position in ICPT in Q3 2018 and held it in 2 quarters. The position peaked at $6.93M in Q3 2018. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

  • HighTower Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • HighTower Advisors sold 38,618 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $3.89M.
  • HighTower Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • HighTower Advisors's Intercept Pharmaceuticals, Inc. position peaked at $6.93M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on HighTower Advisors's 13F filing for Q1 2019, filed 15 May 2019.